Pre-trial Notice; Sample Deposition Designations; Sample Exhibit Objections; ERISA Case Management Order; Sample Pre-Trial Order

=== Pre-trial Notice ===

THIS PRE-TRIAL NOTICE ADOPTED SEPTEMBER 2016 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA PRE-TRIAL NOTICE IT IS ORDERED that a pre-trial conference will be held in Chambers before Judge Jane Triche Milazzo, Section H, in this case on the date and time indicated on the attached scheduling order. The purpose of the pre-trial conference is to secure a just and speedy determination of the issues. If the type of pre-trial order set forth below does not appear calculated to achieve these ends in this case, please arrange a conference with the Judge and opposing counsel immediately so that alternative possibilities may be discussed. The procedure necessary for the preparation of the proposed pre-trial order is as follows: I. The proposed pre-trial order must be electronically filed with the Court by 4:30 p.m. five (5) working days prior to the conference, excluding Saturdays, Sundays, and holidays (i.e., if the conference is set for 8:30 a.m. Friday, it must be filed by 4:30 p.m. the preceding Friday). The proposed pre-trial order shall bear electronic signatures of all counsel at the time it is electronically filed with the Court. Following the pre- trial conference, the Court will issue a minute entry which, inter alia, will APPROVE and ADOPT the pre-trial order, either in its entirety or with specified modifications. II. Counsel for all parties shall confer at their earliest convenience for the purpose of arriving at all possible stipulations and to exchange copies of documents that will be offered in evidence at the trial. It shall be the duty of counsel for plaintiff to initiate this conference, and the duty of other counsel to respond. If, after reasonable effort, any party cannot obtain the cooperation of other counsel, that party shall notify the Court. The conference of counsel shall be held at least ten days prior to the date of the scheduled pre-trial conference. Counsel for all parties shall furnish each other with a statement of the issues that each party plans to offer evidence to support. The parties shall work to eliminate any issues that might appear in the pleadings about which there is no real controversy. The parties’ statements shall include their view of the issues of law remaining in the case, as well as ultimate issues of fact. Counsel for plaintiff shall then prepare a proposed pre-trial order and submit it to opposing counsel. Once any necessary changes are made, counsel for plaintiff shall electronically file the final proposed pre-trial order with the Court. III. At their meeting, counsel must consider the following: A. Jurisdiction. Because jurisdiction may not ever be conferred by consent and because prescription or statutes of limitations may bar a new action if the case or any ancillary demand is dismissed for lack of jurisdiction, counsel should make reasonable effort to ascertain that the Court has jurisdiction. B. Parties. Correctness of identity of legal entities; necessity for appointment of tutor, guardian, administrator, executor, etc., and validity of appointment if already made; correctness of designation of party as partnership, corporation or individual d/b/a trade name. C. Joinder. Questions of misjoinder or nonjoinder of parties. At the pre-trial conference counsel must be fully authorized and prepared to discuss settlement possibilities with the Court. IV. V. The pre-trial conference must be attended by the attorneys who will try the case unless, prior to the conference, the Court grants permission for other counsel to attend. These attorneys will familiarize themselves with the pre-trial rules and will come to the conference with full authority to accomplish the purposes of Rule 16 of the Federal Rules of Civil Procedure. VI. Pre-trial conferences will not be continued except for good cause shown in a written motion presented sufficiently in advance of the conference for opposing counsel to be notified. 2 VII. Failure on the part of counsel to appear at the conference may result in sanctions, including, but not limited to, sua sponte dismissal of the suit, assessment of costs and attorney fees, default, or other appropriate sanctions. All pending motions and all special issues or defenses raised in the pleadings must be called to the court’s attention in the proposed pre-trial order. VIII. IX. 1. 2. 3. 4. The proposed pre-trial order shall set forth the following information: The date of the pre-trial conference. The appearance of counsel identifying the party(s) represented. A description of the parties. In cases of insurance carriers, their insured must be identified. The legal relationships of all parties with reference to the claims, counterclaims, third-party claims, cross claims, etc. a. With respect to jurisdiction, a brief summary of the factual basis supporting each claim asserted, whether original claim, legal and counterclaim, third-party claim, etc., and the jurisdictional basis for each such claim, or if contested, the jurisdictional questions; b. In diversity damage suits, there is authority for dismissing the action, either before or after trial, where it appears that the damages reasonably could not come within the jurisdictional limitation. Therefore, the proposed pre-trial order in such cases shall contain either a stipulation that $75,000 is involved or a summary of the evidence supporting the claim that such sum reasonably could be awarded. 3 5. 6. A list and description of any motions pending or contemplated and any special issues appropriate for determination in advance of trial on the merits. If the Court at any prior hearing has indicated that it would decide certain matters at the time of the pre-trial conference, a brief summary of those matters and the position of each party with respect thereto should be included in the proposed pre-trial order. A brief summary of the material facts claimed by: a. Plaintiff; b. Defendant; c. Other parties. 7. A single listing of all uncontested material facts. 8. A single listing of the contested issues of fact. This does not mean that counsel must concur in a statement of the issues; it simply means that they must list in a single list all issues of fact. Where applicable, particularities concerning the following fact issues shall be set forth: a. Whenever there is in issue the seaworthiness of a vessel or an alleged unsafe condition of property, the material facts and circumstances relied upon to establish the claimed unseaworthy or unsafe condition shall be specified with particularity; b. Whenever there is in issue negligence of the defendant or contributory or comparative negligence of the plaintiff, the material facts and circumstances relied upon to establish the claimed negligence shall be specified with particularity; c. Whenever personal injuries are at issue, the nature and extent of the injuries and of any alleged disability shall be specified with particularity; d. Whenever the alleged breach of a contractual obligation is in issue, the act or omissions relied upon as constituting the claimed breach shall be specified with particularity; e. Whenever the meaning of a contract or other writing is in issue, all facts and circumstances surrounding execution and subsequent to execution, both those admitted and those in issue, which each party contends serve to aid interpretation, shall be specified with particularity; 4 f. g. h. Whenever duress or fraud or mistake is in issue, and set forth in the pleadings, the facts and circumstances relied upon as constituting the claimed duress, fraud, or mistake (see Fed. R. Civ. P. 9(b shall also be set forth in the pre-trial order; If special damages are sought, they shall be itemized with particularity. (See Fed. R. Civ. P. 9(g ; If a conspiracy is charged, the details of facts constituting the conspiracy shall be particularized. 9. A single listing of the contested issues of law. (See explanation in 8 above.) 10. A list and description of the exhibits that each party intends to introduce at the trial. Prior to the confection of the proposed pre-trial order, the parties shall meet, exchange copies of all exhibits, and make a good faith effort to agree as to their authenticity and relevancy. Unless otherwise ordered by the Court, only exhibits included on the exhibit list shall be included for use at trial. a. b. c. Each list of exhibits first should describe those that are to be admitted without objection, and then those to which there will be objection, noting by whom the objection is made (if there are multiple adverse parties), and the nature of the objection. If a party considers he has good cause not to disclose exhibits to be used solely for the purpose of impeachment, he may ex parte request a conference with the Court and make his position known to the Court in camera. Where appropriate to preserve trade secrets or privileges, the listing of exhibits may be made subject to a protective order or in such other fashion as the Court may direct. If there are such exhibits, the proposed pre-trial order will state: “The parties will discuss exhibits alleged to be privileged (or to contain trade secrets, etc.) at the pre-trial conference.” 11. A list of all deposition testimony that each party intends to offer into evidence at trial. 12. A list and brief description of any charts, graphs, models, schematic 5 diagrams, and similar objects which, although not to be offered in evidence, respective counsel intend to use in opening statements or closing arguments. 13. a. A list of witnesses for all parties, including the names, addresses, and statement of the general subject matter of their testimony (it is not sufficient to designate the witness simply “fact,” “medical,” or “expert”), and an indication in good faith of those who will be called in the absence of reasonable notice to opposing counsel to the contrary; b. c. d. A statement that the witness lists were filed in accordance with the Federal Rules of Civil Procedure and prior court orders. No other witnesses shall be allowed unless their addition is agreeable to all parties and does not affect the trial date. This restriction will not apply to rebuttal witnesses or documents whose necessity cannot be reasonably anticipated. Furthermore, in the case of expert witnesses, counsel shall certify that they have exchanged expert reports in accordance with the Federal Rules of Civil Procedure and prior court orders. Expert witnesses whose reports have not been furnished to opposing counsel shall not be permitted to testify nor shall experts be permitted to testify to opinions not included in the reports timely furnished; Except for good cause shown, the Court will not permit any witness to testify unless with respect to such witness there has been complete compliance with all provisions of the pre-trial order and prior court orders; Counsel shall not be allowed to ask questions on cross- examination of an economic expert which would require the witness to make mathematical calculations in order to frame a response unless the factual elements of such questions shall have been submitted to that expert witness at least three full working days before trial. 14. A statement indicating whether the case is a jury or non-jury case. a. If the case is a jury case, then indicate whether the jury trial is applicable to all aspects of the case or only to certain issues, which issues shall be specified. In jury cases, add the following provisions: 6 “Proposed jury instructions, special jury interrogatories, and voir dire shall be electronically filed with the Court not later than five working days prior to the trial date.” b. c. In a non-jury case, suggested findings of fact and conclusions of law and a separate trial memorandum are required, unless the Court enters an order that such is not required. Same are to be electronically filed not less than ten full working days prior to trial. In a jury case, a trial memorandum shall be required only when and to the extent ordered by the Court. If, however, counsel anticipates unique evidentiary problems, a memo addressing the same should be filed electronically not less than 5 working days prior to trial. Likewise, briefing on any unusual jury instructions requiring explanation beyond mere citation to authority shall be filed at this time. 15. In cases where damages are sought, include a statement that: “The issue of liability (will or will not) be tried separately from that of quantum.” 16. A statement describing any other matters that might expedite a disposition of the case. 17. A statement that trial shall commence on [month/day] , _[year] at [time] a.m./p.m. and a realistic estimate of the number of trial days required. Where counsel cannot agree upon the number of trial days required, the estimate of each side should be given. 18. The statement that “This pre-trial order has been formulated after conference at which counsel for the respective parties have appeared in person. Reasonable opportunity has been afforded counsel for corrections, or additions, prior to signing. Hereafter, this order will control the course of the trial and may not be amended except by consent of the parties and the Court, or by order of the Court to prevent manifest injustice.” 19. The statement that “Possibility of settlement of this case was considered.” 20. The proposed pre-trial order must contain appropriate signature spaces for counsel for all parties. 21. Each numbered paragraph of the proposed pre-trial order shall be 7 preceded by a heading descriptive of its content. IT IS FURTHER ORDERED that the foregoing pre-trial notice be mailed to counsel of record for all parties to this case, and that counsel will comply with the directions set forth herein. New Orleans, Louisiana ___________________________________ JANE TRICHE MILAZZO UNITED STATES DISTRICT JUDGE 8

=== Sample Deposition Designations ===

Sample for Objections to Deposition Designations Judge Jane Triche Milazzo Objections to deposition designations should be indicated as follows: Color 1: Deposition testimony that one party wishes to admit and to which there is no objection. Color 2: Deposition testimony that Plaintiff wishes to admit but to which Defendant objects. An explanation of the objection should be indicated in a corresponding text box. Color 3: Deposition testimony that Defendant wishes to admit but to which Plaintiff objects. An explanation of the objection should be indicated in a corresponding text box. Those portions of the deposition which are not highlighted in any color are those portions which no party wishes to admit at trial. (cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:6)(cid:4)(cid:2) (cid:26)(cid:5)(cid:5) (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 $(cid:8) ! (cid:22)(cid:25) (cid:22)=(cid:22).(cid:12)(cid:8) ! (cid:22)(cid:25) (cid:22)=(cid:22).(cid:12)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) $(cid:23)(cid:14) 2(cid:12) ,(cid:16).=(cid:22).(cid:14)(cid:12)(cid:14) (cid:22) (cid:24)(cid:16)(cid:15)5 (cid:16), (cid:13)2(cid:22)(cid:13) %4(cid:22)5(cid:8) $(cid:23)(cid:14) 2(cid:12) ,(cid:16).=(cid:22).(cid:14)(cid:12)(cid:14) (cid:22) (cid:24)(cid:16)(cid:15)5 (cid:16), (cid:13)2(cid:22)(cid:13) 3(cid:8) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:13)(cid:16) 5(cid:16)6* (cid:22)(cid:18)(cid:16)(cid:23)(cid:21) =(cid:20)(cid:13)2 ’(cid:16)- ?6(cid:25)(cid:15)2.(cid:12)5(cid:11) (cid:22)(cid:23)(cid:14) B(cid:12)(cid:23)(cid:13) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:13)(cid:16) 5(cid:16)6* (cid:22)(cid:18)(cid:16)(cid:23)(cid:21) =(cid:20)(cid:13)2 ’(cid:16)- ?6(cid:25)(cid:15)2.(cid:12)5(cid:11) (cid:22)(cid:23)(cid:14) B(cid:12)(cid:23)(cid:13) #.6-(cid:12).* (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 #.6-(cid:12).* (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 $(cid:8) 7(cid:12)(cid:11)(cid:8) 7(cid:12)(cid:11)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) F2(cid:22)(cid:13) (cid:14)(cid:20)(cid:14) 5(cid:16)6 (cid:14)(cid:16) (cid:20)(cid:23) .(cid:12)(cid:11)(cid:15)(cid:16)(cid:23)(cid:11)(cid:12) (cid:13)(cid:16) %4(cid:22)5(cid:8) F2(cid:22)(cid:13) (cid:14)(cid:20)(cid:14) 5(cid:16)6 (cid:14)(cid:16) (cid:20)(cid:23) .(cid:12)(cid:11)(cid:15)(cid:16)(cid:23)(cid:11)(cid:12) (cid:13)(cid:16) 3(cid:8) .(cid:12)(cid:24)(cid:12)(cid:20)1(cid:20)(cid:23)(cid:21) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)0 .(cid:12)(cid:24)(cid:12)(cid:20)1(cid:20)(cid:23)(cid:21) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)0 $(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12).(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12).(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:22)(cid:23)5 (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:22)(cid:23)5 (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) 3(cid:8) (cid:20)(cid:23)(cid:13)(cid:12).(cid:23)(cid:22)(cid:18)(cid:18)5 =(cid:20)(cid:13)2(cid:20)(cid:23 .(cid:20)(cid:25)(cid:12) +(cid:16)(cid:23)(cid:14)6(cid:20)(cid:13) (cid:22)-(cid:16)6(cid:13) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:20)(cid:23)(cid:13)(cid:12).(cid:23)(cid:22)(cid:18)(cid:18)5 =(cid:20)(cid:13)2(cid:20)(cid:23 .(cid:20)(cid:25)(cid:12) +(cid:16)(cid:23)(cid:14)6(cid:20)(cid:13) (cid:22)-(cid:16)6(cid:13) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)0 (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)0 $(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:22)(cid:23)5 (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:16)(cid:23)(cid:12)(cid:11)(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:22)(cid:23)5 (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:16)(cid:23)(cid:12)(cid:11)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) 2(cid:22)1(cid:20)(cid:23)(cid:21) (cid:22)(cid:23)5 %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) 2(cid:22)1(cid:20)(cid:23)(cid:21) (cid:22)(cid:23)5 3(cid:8) (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) (cid:22),(cid:13)(cid:12). .(cid:12)(cid:24)(cid:12)(cid:20)1(cid:20)(cid:23)(cid:21) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) (cid:22),(cid:13)(cid:12). .(cid:12)(cid:24)(cid:12)(cid:20)1(cid:20)(cid:23)(cid:21) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23)>(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:22)-(cid:16)6(cid:13) (cid:22)(cid:15)(cid:15).(cid:16)(cid:15).(cid:20)(cid:22)(cid:13)(cid:12) (cid:14)(cid:20)(cid:11)(cid:13)(cid:22)(cid:23)(cid:24)(cid:12)(cid:11) ,(cid:16). (cid:15)6(cid:18)(cid:18) -(cid:16)(cid:19)(cid:12)(cid:11)0 (cid:22)-(cid:16)6(cid:13) (cid:22)(cid:15)(cid:15).(cid:16)(cid:15).(cid:20)(cid:22)(cid:13)(cid:12) (cid:14)(cid:20)(cid:11)(cid:13)(cid:22)(cid:23)(cid:24)(cid:12)(cid:11) ,(cid:16). (cid:15)6(cid:18)(cid:18) -(cid:16)(cid:19)(cid:12)(cid:11)0 $(cid:8) ! (cid:24)(cid:22)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12). (cid:22)(cid:23)5 (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:16)(cid:23)(cid:12)(cid:11)(cid:8) ! (cid:24)(cid:22)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12). (cid:22)(cid:23)5 (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:16)(cid:23)(cid:12)(cid:11)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) ?(cid:22)1(cid:12) 5(cid:16)6 (cid:12)1(cid:12). 2(cid:22)(cid:14) (cid:22)(cid:23)5 (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) %4(cid:22)5(cid:8) ?(cid:22)1(cid:12) 5(cid:16)6 (cid:12)1(cid:12). 2(cid:22)(cid:14) (cid:22)(cid:23)5 (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23)(cid:11) 3(cid:8) =(cid:20)(cid:13)2 (cid:22)(cid:23)5(cid:16)(cid:23)(cid:12) =(cid:20)(cid:13)2 ?(cid:22).(cid:15)(cid:12). .(cid:12)(cid:21)(cid:22).(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) (cid:16)(cid:23) =(cid:20)(cid:13)2 (cid:22)(cid:23)5(cid:16)(cid:23)(cid:12) =(cid:20)(cid:13)2 ?(cid:22).(cid:15)(cid:12). .(cid:12)(cid:21)(cid:22).(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) (cid:16)(cid:23) (cid:13)2(cid:12) !"C (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13)0 (cid:13)2(cid:12) !"C (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13)0 $(cid:8) &(cid:16)(cid:8) &(cid:16)(cid:8) $(cid:8) PCI objects to p. 344, lines 22-25, p. 345, lines 1-25, & p. 346, lines 1-3. This testimony discusses an email from Madigan to Gruber dated 1/28/2010, identified in the PTO as Exhibit JBH 7. The e-mail constitutes hearsay and no foundation is laid to establish its admissibility. Moreover, the e-mail contains hearsay within hearsay. 3(cid:8) (cid:30)(cid:22).(cid:18)(cid:20)(cid:12). =(cid:20)(cid:13)2 H(cid:20)(cid:25) =(cid:12) (cid:18)(cid:16)(cid:16)4(cid:12)(cid:14) (cid:22)(cid:13) (cid:22) (cid:30)(cid:22).(cid:18)(cid:20)(cid:12). =(cid:20)(cid:13)2 H(cid:20)(cid:25) =(cid:12) (cid:18)(cid:16)(cid:16)4(cid:12)(cid:14) (cid:22)(cid:13) (cid:22) 3(cid:8) Harper's Response: Not being offered for truth; Madigan email is party admission. H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)* (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:13)2(cid:12) H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)* (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:13)2(cid:12) (cid:12)(cid:19)2(cid:20)-(cid:20)(cid:13) (cid:23)6(cid:25)-(cid:12).* -6(cid:13) (cid:20)(cid:13) (cid:11)2(cid:16)6(cid:18)(cid:14) -(cid:12) (cid:20)(cid:23) ,.(cid:16)(cid:23)(cid:13) (cid:16), 5(cid:16)6(cid:8) (cid:12)(cid:19)2(cid:20)-(cid:20)(cid:13) (cid:23)6(cid:25)-(cid:12).* -6(cid:13) (cid:20)(cid:13) (cid:11)2(cid:16)6(cid:18)(cid:14) -(cid:12) (cid:20)(cid:23) ,.(cid:16)(cid:23)(cid:13) (cid:16), 5(cid:16)6(cid:8) %4(cid:22)5(cid:8) (cid:30)(cid:19)2(cid:20)-(cid:20)(cid:13) (cid:4)(cid:26) (cid:20)(cid:11) =2(cid:22)(cid:13) !>(cid:25) .(cid:12),(cid:12)..(cid:20)(cid:23)(cid:21) %4(cid:22)5(cid:8) (cid:30)(cid:19)2(cid:20)-(cid:20)(cid:13) (cid:4)(cid:26) (cid:20)(cid:11) =2(cid:22)(cid:13) !>(cid:25) .(cid:12),(cid:12)..(cid:20)(cid:23)(cid:21) (cid:4) (cid:4) (cid:2) (cid:2) (cid:26) (cid:26) (cid:5) (cid:5) (cid:7) (cid:7) (cid:28) (cid:28) (cid:9) (cid:9) (cid:10) (cid:10) (cid:27) (cid:27) (cid:4)(cid:6) (cid:4)(cid:6) (cid:4)(cid:4) (cid:4)(cid:4) (cid:4)(cid:2) (cid:4)(cid:2) (cid:4)(cid:26) (cid:4)(cid:26) (cid:4)(cid:5) (cid:4)(cid:5) (cid:4)(cid:7) (cid:4)(cid:7) (cid:4)(cid:28) (cid:4)(cid:28) (cid:4)(cid:9) (cid:4)(cid:9) (cid:4)(cid:10) (cid:4)(cid:10) (cid:4)(cid:27) (cid:4)(cid:27) (cid:2)(cid:6) (cid:2)(cid:6) (cid:2)(cid:4) (cid:2)(cid:4) (cid:2)(cid:2) (cid:2)(cid:2) (cid:2)(cid:26) (cid:2)(cid:26) (cid:2)(cid:5) (cid:2)(cid:5) (cid:2)(cid:7) (cid:2)(cid:7) (cid:26)(cid:26)(cid:9)(cid:8)(cid:2)(cid:28)(cid:28)(cid:8)(cid:2)(cid:4)(cid:6)(cid:2) (cid:7)(cid:6)(cid:5)(cid:8)(cid:9)(cid:2)(cid:2)(cid:8)(cid:4)(cid:10)(cid:6)(cid:4) (cid:29)(cid:30)(cid:31) (cid:29)!"!#$"!%& #’%()* (cid:29)(cid:29)+ (cid:11)(cid:12)(cid:13)(cid:14)(cid:12)(cid:15)(cid:16)(cid:17)(cid:18)(cid:12)(cid:19)(cid:18)(cid:20)(cid:13)(cid:20)(cid:21)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23)(cid:8)(cid:24)(cid:16)(cid:25) (cid:2)(cid:7)(cid:7)(cid:8)(cid:2)(cid:27)(cid:4)(cid:28)(cid:7)(cid:27)(cid:7) (cid:9)(cid:4)(cid:26)(cid:8)(cid:10)(cid:6)(cid:7)(cid:8)(cid:27)(cid:2)(cid:5)(cid:27) (cid:14)(cid:15)(cid:11)(cid:16)(cid:17)(cid:18)(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:15)(cid:15)(cid:23)(cid:24)(cid:25)(cid:21)(cid:26)(cid:20)(cid:11)(cid:5)(cid:24)(cid:27)(cid:23)(cid:24)(cid:28)(cid:22)(cid:18)(cid:21)(cid:24)(cid:29)(cid:30)(cid:24)(cid:31)(cid:11) (cid:22)(cid:20)(cid:24)!(cid:8)(cid:4)(cid:2)(cid:7)(cid:2)"(cid:3)(cid:7)(cid:3)(cid:13)"(cid:7)(cid:12)(cid:9)(cid:13)(cid:13)# (cid:2)(cid:3)(cid:4)(cid:5)(cid:2)(cid:2)(cid:6)(cid:6)(cid:7)(cid:5)(cid:5)(cid:8)(cid:6)(cid:7)(cid:8)(cid:6)(cid:4)(cid:3)(cid:7)(cid:6)(cid:8)(cid:3)(cid:4)(cid:7)(cid:9)(cid:9)(cid:10)(cid:4)(cid:11)(cid:5)(cid:12)(cid:13)(cid:8)(cid:11)(cid:2)(cid:6) (cid:13)(cid:16)* =2(cid:20)(cid:24)2 5(cid:16)6>1(cid:12) (cid:21)(cid:16)(cid:13) (cid:20)(cid:23) ,.(cid:16)(cid:23)(cid:13) (cid:16), 5(cid:16)6A (cid:20)(cid:11) (cid:13)2(cid:22)(cid:13) (cid:13)(cid:16)* =2(cid:20)(cid:24)2 5(cid:16)6>1(cid:12) (cid:21)(cid:16)(cid:13) (cid:20)(cid:23) ,.(cid:16)(cid:23)(cid:13) (cid:16), 5(cid:16)6A (cid:20)(cid:11) (cid:13)2(cid:22)(cid:13) (cid:26)(cid:5)(cid:7) (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 $(cid:8) 7(cid:12)(cid:11)(cid:8) 7(cid:12)(cid:11)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) "2(cid:12) (cid:13)(cid:16)(cid:15) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:20)(cid:11) ,.(cid:16)(cid:25) ’(cid:16)- %4(cid:22)5(cid:8) "2(cid:12) (cid:13)(cid:16)(cid:15) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:20)(cid:11) ,.(cid:16)(cid:25) ’(cid:16)- 3(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) (cid:13)(cid:16) B(cid:12)(cid:23)(cid:13) #.6-(cid:12). =(cid:20)(cid:13)2 (cid:22) (cid:24)(cid:16)(cid:15)5 (cid:13)(cid:16) ’(cid:16)- ?6(cid:25)(cid:15)2.(cid:12)5(cid:11) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) (cid:13)(cid:16) B(cid:12)(cid:23)(cid:13) #.6-(cid:12). =(cid:20)(cid:13)2 (cid:22) (cid:24)(cid:16)(cid:15)5 (cid:13)(cid:16) ’(cid:16)- ?6(cid:25)(cid:15)2.(cid:12)5(cid:11) (cid:22)(cid:23)(cid:14) 5(cid:16)6 (cid:14)(cid:22)(cid:13)(cid:12)(cid:14) H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)(cid:8) @(cid:16) 5(cid:16)6 (cid:11)(cid:12)(cid:12) (cid:13)2(cid:22)(cid:13)0 (cid:22)(cid:23)(cid:14) 5(cid:16)6 (cid:14)(cid:22)(cid:13)(cid:12)(cid:14) H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)(cid:8) @(cid:16) 5(cid:16)6 (cid:11)(cid:12)(cid:12) (cid:13)2(cid:22)(cid:13)0 $(cid:8) ! (cid:14)(cid:16)(cid:8) ! (cid:14)(cid:16)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) $(cid:23)(cid:14) (cid:20)(cid:23) (cid:13)2(cid:20)(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)* 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) %4(cid:22)5(cid:8) $(cid:23)(cid:14) (cid:20)(cid:23) (cid:13)2(cid:20)(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)* 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) 3(cid:8) (cid:14)(cid:12)(cid:11)(cid:24).(cid:20)-(cid:12)(cid:11) (cid:22) (cid:13)(cid:12)(cid:18)(cid:12)(cid:15)2(cid:16)(cid:23)(cid:12) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23) 2(cid:12) 2(cid:22)(cid:14) =(cid:20)(cid:13)2 +2(cid:20)(cid:15) +2(cid:20)(cid:15) (cid:14)(cid:12)(cid:11)(cid:24).(cid:20)-(cid:12)(cid:11) (cid:22) (cid:13)(cid:12)(cid:18)(cid:12)(cid:15)2(cid:16)(cid:23)(cid:12) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23) 2(cid:12) 2(cid:22)(cid:14) =(cid:20)(cid:13)2 (cid:22)(cid:23)(cid:14) "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23)* (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 (cid:22)(cid:23)(cid:14) "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23)* (cid:24)(cid:16)..(cid:12)(cid:24)(cid:13)0 $(cid:8) +(cid:16)..(cid:12)(cid:24)(cid:13)(cid:8) +(cid:16)..(cid:12)(cid:24)(cid:13)(cid:8) $(cid:8) 3(cid:8) @(cid:16) 5(cid:16)6 4(cid:23)(cid:16)= +2(cid:20)(cid:15) (cid:22)(cid:23)(cid:14) "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23) (cid:13)(cid:16) -(cid:12) @(cid:16) 5(cid:16)6 4(cid:23)(cid:16)= +2(cid:20)(cid:15) (cid:22)(cid:23)(cid:14) "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23) (cid:13)(cid:16) -(cid:12) 3(cid:8) (cid:22),,(cid:20)(cid:18)(cid:20)(cid:22)(cid:13)(cid:12)(cid:14) =(cid:20)(cid:13)2 ?(cid:22).(cid:15)(cid:12).0 (cid:22),,(cid:20)(cid:18)(cid:20)(cid:22)(cid:13)(cid:12)(cid:14) =(cid:20)(cid:13)2 ?(cid:22).(cid:15)(cid:12).0 $(cid:8) +2(cid:20)(cid:15)* 5(cid:12)(cid:11)(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) 4(cid:23)(cid:16)= "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23)(cid:8) +2(cid:20)(cid:15)* 5(cid:12)(cid:11)(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) 4(cid:23)(cid:16)= "(cid:16)(cid:14)(cid:14) $(cid:18)(cid:18)(cid:12)(cid:23)(cid:8) $(cid:8) 3(cid:8) %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) %4(cid:22)5(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) 3(cid:8) (cid:22)(cid:14)1(cid:20)(cid:11)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:22)(cid:13) ?(cid:22).(cid:15)(cid:12). =(cid:22)(cid:11) (cid:24)(cid:16)(cid:23)(cid:13)(cid:20)(cid:23)6(cid:20)(cid:23)(cid:21) (cid:13)(cid:16) 2(cid:22)1(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) (cid:22)(cid:14)1(cid:20)(cid:11)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:22)(cid:13) ?(cid:22).(cid:15)(cid:12). =(cid:22)(cid:11) (cid:24)(cid:16)(cid:23)(cid:13)(cid:20)(cid:23)6(cid:20)(cid:23)(cid:21) (cid:13)(cid:16) 2(cid:22)1(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) =(cid:20)(cid:13)2 (cid:12)(cid:19)(cid:15)(cid:22)(cid:23)(cid:11)(cid:20)(cid:16)(cid:23) /(cid:16)(cid:20)(cid:23)(cid:13)(cid:11) (cid:22),(cid:13)(cid:12). (cid:13)2(cid:12) H(cid:22)(cid:23)6(cid:22).5 (cid:20)(cid:23)(cid:11)(cid:15)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23)0 =(cid:20)(cid:13)2 (cid:12)(cid:19)(cid:15)(cid:22)(cid:23)(cid:11)(cid:20)(cid:16)(cid:23) /(cid:16)(cid:20)(cid:23)(cid:13)(cid:11) (cid:22),(cid:13)(cid:12). (cid:13)2(cid:12) H(cid:22)(cid:23)6(cid:22).5 (cid:20)(cid:23)(cid:11)(cid:15)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23)0 $(cid:8) !>(cid:25) .(cid:12)(cid:22)(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:24)(cid:16)(cid:23)(cid:13)(cid:12)(cid:23)(cid:13) (cid:16), (cid:13)2(cid:12) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)(cid:8) !>(cid:25) .(cid:12)(cid:22)(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:24)(cid:16)(cid:23)(cid:13)(cid:12)(cid:23)(cid:13) (cid:16), (cid:13)2(cid:12) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)(cid:8) $(cid:8) 3(cid:8) F(cid:12)(cid:18)(cid:18)* (cid:16)(cid:13)2(cid:12). (cid:13)2(cid:22)(cid:23) .(cid:12)(cid:22)(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:24)(cid:16)(cid:23)(cid:13)(cid:12)(cid:23)(cid:13) (cid:16), F(cid:12)(cid:18)(cid:18)* (cid:16)(cid:13)2(cid:12). (cid:13)2(cid:22)(cid:23) .(cid:12)(cid:22)(cid:14)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:24)(cid:16)(cid:23)(cid:13)(cid:12)(cid:23)(cid:13) (cid:16), 3(cid:8) (cid:13)2(cid:12) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)* (cid:14)(cid:16) 5(cid:16)6 2(cid:22)1(cid:12) (cid:22)(cid:23)5 .(cid:12)(cid:24)(cid:16)(cid:18)(cid:18)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23) (cid:16), -(cid:12)(cid:20)(cid:23)(cid:21) (cid:13)2(cid:12) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18)* (cid:14)(cid:16) 5(cid:16)6 2(cid:22)1(cid:12) (cid:22)(cid:23)5 .(cid:12)(cid:24)(cid:16)(cid:18)(cid:18)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23) (cid:16), -(cid:12)(cid:20)(cid:23)(cid:21) (cid:22)(cid:15)(cid:15).(cid:20)(cid:11)(cid:12)(cid:14) (cid:16), (cid:13)2(cid:22)(cid:13) ,(cid:22)(cid:24)(cid:13)0 (cid:22)(cid:15)(cid:15).(cid:20)(cid:11)(cid:12)(cid:14) (cid:16), (cid:13)2(cid:22)(cid:13) ,(cid:22)(cid:24)(cid:13)0 $(cid:8) ! /6(cid:11)(cid:13) (cid:14)(cid:16)(cid:23)>(cid:13) 2(cid:22)1(cid:12) (cid:22) .(cid:12)(cid:24)(cid:16)(cid:18)(cid:18)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23) (cid:16), (cid:22) ! /6(cid:11)(cid:13) (cid:14)(cid:16)(cid:23)>(cid:13) 2(cid:22)1(cid:12) (cid:22) .(cid:12)(cid:24)(cid:16)(cid:18)(cid:18)(cid:12)(cid:24)(cid:13)(cid:20)(cid:16)(cid:23) (cid:16), (cid:22) $(cid:8) (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23) (cid:22)-(cid:16)6(cid:13) (cid:20)(cid:13)(cid:8) (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23) (cid:22)-(cid:16)6(cid:13) (cid:20)(cid:13)(cid:8) 3(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:23)(cid:21) (cid:22)(cid:23)5 (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) @(cid:16) 5(cid:16)6 .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:23)(cid:21) (cid:22)(cid:23)5 (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) 3(cid:8) .(cid:12)(cid:18)(cid:22)(cid:13)(cid:12)(cid:14) (cid:13)(cid:16) (cid:13)2(cid:12) ?(cid:22).(cid:15)(cid:12). !"C (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13) =(cid:20)(cid:13)2 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) .(cid:12)(cid:18)(cid:22)(cid:13)(cid:12)(cid:14) (cid:13)(cid:16) (cid:13)2(cid:12) ?(cid:22).(cid:15)(cid:12). !"C (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13) =(cid:20)(cid:13)2 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) (cid:4) (cid:4) (cid:2) (cid:2) (cid:26) (cid:26) (cid:5) (cid:5) (cid:7) (cid:7) (cid:28) (cid:28) (cid:9) (cid:9) (cid:10) (cid:10) (cid:27) (cid:27) (cid:4)(cid:6) (cid:4)(cid:6) (cid:4)(cid:4) (cid:4)(cid:4) (cid:4)(cid:2) (cid:4)(cid:2) (cid:4)(cid:26) (cid:4)(cid:26) (cid:4)(cid:5) (cid:4)(cid:5) (cid:4)(cid:7) (cid:4)(cid:7) (cid:4)(cid:28) (cid:4)(cid:28) (cid:4)(cid:9) (cid:4)(cid:9) (cid:4)(cid:10) (cid:4)(cid:10) (cid:4)(cid:27) (cid:4)(cid:27) (cid:2)(cid:6) (cid:2)(cid:6) (cid:2)(cid:4) (cid:2)(cid:4) (cid:2)(cid:2) (cid:2)(cid:2) (cid:2)(cid:26) (cid:2)(cid:26) (cid:2)(cid:5) (cid:2)(cid:5) (cid:2)(cid:7) (cid:2)(cid:7) (cid:26)(cid:26)(cid:9)(cid:8)(cid:2)(cid:28)(cid:28)(cid:8)(cid:2)(cid:4)(cid:6)(cid:2) (cid:7)(cid:6)(cid:5)(cid:8)(cid:9)(cid:2)(cid:2)(cid:8)(cid:4)(cid:10)(cid:6)(cid:4) (cid:29)(cid:30)(cid:31) (cid:29)!"!#$"!%& #’%()* (cid:29)(cid:29)+ (cid:11)(cid:12)(cid:13)(cid:14)(cid:12)(cid:15)(cid:16)(cid:17)(cid:18)(cid:12)(cid:19)(cid:18)(cid:20)(cid:13)(cid:20)(cid:21)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23)(cid:8)(cid:24)(cid:16)(cid:25) (cid:2)(cid:7)(cid:7)(cid:8)(cid:2)(cid:27)(cid:4)(cid:28)(cid:7)(cid:27)(cid:7) (cid:9)(cid:4)(cid:26)(cid:8)(cid:10)(cid:6)(cid:7)(cid:8)(cid:27)(cid:2)(cid:5)(cid:27) (cid:14)(cid:15)(cid:11)(cid:16)(cid:17)(cid:18)(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:15)(cid:15)(cid:23)(cid:24)(cid:25)(cid:21)(cid:26)(cid:20)(cid:11)(cid:5)(cid:24)(cid:27)(cid:23)(cid:24)(cid:28)(cid:22)(cid:18)(cid:21)(cid:24)(cid:29)(cid:30)(cid:24)(cid:31)(cid:11) (cid:22)(cid:20)(cid:24)!(cid:8)(cid:4)(cid:2)(cid:7)(cid:2)"(cid:3)(cid:7)(cid:3)(cid:13)"(cid:7)(cid:12)(cid:9)(cid:13)(cid:13)# (cid:2)(cid:3)(cid:4)(cid:5)(cid:2)(cid:2)(cid:6)(cid:6)(cid:7)(cid:5)(cid:5)(cid:8)(cid:6)(cid:7)(cid:8)(cid:6)(cid:4)(cid:3)(cid:7)(cid:6)(cid:8)(cid:3)(cid:4)(cid:7)(cid:9)(cid:9)(cid:10)(cid:4)(cid:11)(cid:5)(cid:12)(cid:13)(cid:8)(cid:11)(cid:2)(cid:6) (cid:2)(cid:3)(cid:4)(cid:5)(cid:3)(cid:2)(cid:6)(cid:4)(cid:2) (cid:26)(cid:5)(cid:28) (cid:22),(cid:13)(cid:12). .(cid:12)(cid:24)(cid:12)(cid:20)(cid:15)(cid:13) (cid:16), (cid:13)2(cid:20)(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:20)(cid:23) H(cid:22)(cid:23)6(cid:22).5 (cid:16), (cid:2)(cid:6)(cid:4)(cid:6)0 (cid:22),(cid:13)(cid:12). .(cid:12)(cid:24)(cid:12)(cid:20)(cid:15)(cid:13) (cid:16), (cid:13)2(cid:20)(cid:11) (cid:12)8(cid:25)(cid:22)(cid:20)(cid:18) (cid:20)(cid:23) H(cid:22)(cid:23)6(cid:22).5 (cid:16), (cid:2)(cid:6)(cid:4)(cid:6)0 $(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23)(cid:11) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:24)(cid:22)(cid:18)(cid:18) (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24) (cid:24)(cid:16)(cid:23)1(cid:12).(cid:11)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23)(cid:11) $(cid:8) (cid:22)-(cid:16)6(cid:13) (cid:20)(cid:13)(cid:8) (cid:22)-(cid:16)6(cid:13) (cid:20)(cid:13)(cid:8) 3(cid:8) @(cid:20)(cid:14) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) 2(cid:22)1(cid:12) (cid:22)(cid:23)5 (cid:24)(cid:16)(cid:23)(cid:13)(cid:20)(cid:23)6(cid:12)(cid:14) @(cid:20)(cid:14) 9.(cid:8) 9(cid:22)(cid:14)(cid:20)(cid:21)(cid:22)(cid:23) 2(cid:22)1(cid:12) (cid:22)(cid:23)5 (cid:24)(cid:16)(cid:23)(cid:13)(cid:20)(cid:23)6(cid:12)(cid:14) 3(cid:8) (cid:20)(cid:23)1(cid:16)(cid:18)1(cid:12)(cid:25)(cid:12)(cid:23)(cid:13) (cid:16)(cid:23) -(cid:12)2(cid:22)(cid:18), (cid:16), ).(cid:20)(cid:25)(cid:12) +(cid:16)(cid:23)(cid:14)6(cid:20)(cid:13) (cid:22),(cid:13)(cid:12). (cid:16)(cid:23) -(cid:12)2(cid:22)(cid:18), (cid:16), ).(cid:20)(cid:25)(cid:12) +(cid:16)(cid:23)(cid:14)6(cid:20)(cid:13) (cid:22),(cid:13)(cid:12). (cid:20)(cid:23)1(cid:16)(cid:18)1(cid:12)(cid:25)(cid:12)(cid:23)(cid:13) H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)0 H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)0 $(cid:8) $(cid:11) =(cid:22)(cid:11) (cid:25)(cid:12)(cid:23)(cid:13)(cid:20)(cid:16)(cid:23)(cid:12)(cid:14) (cid:12)(cid:22).(cid:18)(cid:20)(cid:12).* ! 4(cid:23)(cid:16)= 2(cid:12) =(cid:12)(cid:23)(cid:13) $(cid:11) =(cid:22)(cid:11) (cid:25)(cid:12)(cid:23)(cid:13)(cid:20)(cid:16)(cid:23)(cid:12)(cid:14) (cid:12)(cid:22).(cid:18)(cid:20)(cid:12).* ! 4(cid:23)(cid:16)= 2(cid:12) =(cid:12)(cid:23)(cid:13) $(cid:8) (cid:16)(cid:23) (cid:22)(cid:23)(cid:16)(cid:13)2(cid:12). 1(cid:20)(cid:11)(cid:20)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:11)(cid:20)(cid:13)(cid:12)(cid:8) (cid:16)(cid:23) (cid:22)(cid:23)(cid:16)(cid:13)2(cid:12). 1(cid:20)(cid:11)(cid:20)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:11)(cid:20)(cid:13)(cid:12)(cid:8) 3(cid:8) @(cid:20)(cid:14) 5(cid:16)6 (cid:25)(cid:22)4(cid:12) (cid:22) 1(cid:20)(cid:11)(cid:20)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:11)(cid:20)(cid:13)(cid:12) (cid:16)(cid:23) (cid:13)2(cid:22)(cid:13) @(cid:20)(cid:14) 5(cid:16)6 (cid:25)(cid:22)4(cid:12) (cid:22) 1(cid:20)(cid:11)(cid:20)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:11)(cid:20)(cid:13)(cid:12) (cid:16)(cid:23) (cid:13)2(cid:22)(cid:13) 3(cid:8) (cid:16)(cid:24)(cid:24)(cid:22)(cid:11)(cid:20)(cid:16)(cid:23)0 (cid:16)(cid:24)(cid:24)(cid:22)(cid:11)(cid:20)(cid:16)(cid:23)0 $(cid:8) ! (cid:14)(cid:20)(cid:14) (cid:23)(cid:16)(cid:13)(cid:8) ! (cid:14)(cid:20)(cid:14) (cid:23)(cid:16)(cid:13)(cid:8) $(cid:8) 3(cid:8) ?(cid:22)1(cid:12) 5(cid:16)6 (cid:12)1(cid:12). 88 ?(cid:22)1(cid:12) 5(cid:16)6 (cid:12)1(cid:12). 3(cid:8) $(cid:8) ! 2(cid:22)1(cid:12) (cid:23)(cid:16)(cid:13)(cid:8) 3(cid:8) 88 -(cid:12)(cid:12)(cid:23) (cid:14)(cid:16)=(cid:23) (cid:13)(cid:16) (cid:13)2(cid:12) /(cid:16)- (cid:11)(cid:20)(cid:13)(cid:12)0 $(cid:8) !>(cid:25) (cid:11)(cid:16)..5(cid:8) ! (cid:14)(cid:20)(cid:14) (cid:23)(cid:16)(cid:13) 88 ! 2(cid:22)1(cid:12) (cid:23)(cid:16)(cid:13)(cid:8) 3(cid:8) F2(cid:22)(cid:13) ,6.(cid:13)2(cid:12). (cid:20)(cid:23)1(cid:16)(cid:18)1(cid:12)(cid:25)(cid:12)(cid:23)(cid:13) (cid:14)(cid:20)(cid:14) 5(cid:16)6 2(cid:22)1(cid:12) F2(cid:22)(cid:13) ,6.(cid:13)2(cid:12). (cid:20)(cid:23)1(cid:16)(cid:18)1(cid:12)(cid:25)(cid:12)(cid:23)(cid:13) (cid:14)(cid:20)(cid:14) 5(cid:16)6 2(cid:22)1(cid:12) 3(cid:8) =(cid:20)(cid:13)2 .(cid:12)(cid:11)(cid:15)(cid:12)(cid:24)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) (cid:16)(cid:23) (cid:13)2(cid:12) ?(cid:22).(cid:15)(cid:12). !"C =(cid:20)(cid:13)2 .(cid:12)(cid:11)(cid:15)(cid:12)(cid:24)(cid:13) (cid:13)(cid:16) (cid:13)2(cid:12) (cid:15).(cid:16)-(cid:18)(cid:12)(cid:25)(cid:11) (cid:16)(cid:23) (cid:13)2(cid:12) ?(cid:22).(cid:15)(cid:12). !"C (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13) (cid:22),(cid:13)(cid:12). H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)0 (cid:15).(cid:16)/(cid:12)(cid:24)(cid:13) (cid:22),(cid:13)(cid:12). H(cid:22)(cid:23)6(cid:22).5 (cid:2)(cid:10)(cid:13)2* (cid:2)(cid:6)(cid:4)(cid:6)0 $(cid:8) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12). (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24)(cid:22)(cid:18)(cid:18)5 =2(cid:22)(cid:13) =(cid:12)(cid:23)(cid:13) ! (cid:14)(cid:16)(cid:23)>(cid:13) .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12). (cid:11)(cid:15)(cid:12)(cid:24)(cid:20),(cid:20)(cid:24)(cid:22)(cid:18)(cid:18)5 =2(cid:22)(cid:13) =(cid:12)(cid:23)(cid:13) $(cid:8) (cid:16)(cid:23) (cid:22),(cid:13)(cid:12). (cid:13)2(cid:22)(cid:13) (cid:15)(cid:16)(cid:20)(cid:23)(cid:13)(cid:8) (cid:16)(cid:23) (cid:22),(cid:13)(cid:12). (cid:13)2(cid:22)(cid:13) (cid:15)(cid:16)(cid:20)(cid:23)(cid:13)(cid:8) 3(cid:8) @(cid:16) 5(cid:16)6 .(cid:12)(cid:25)(cid:12)(cid:25)-(cid:12). (cid:21)(cid:12)(cid:23)(cid:12).(cid:22)(cid:18)(cid:18)5 (cid:22)(cid:23)5 (cid:20)(cid:23)1(cid:16)(cid:18)1(cid:12)(cid:25)(cid:12)(cid:23)(cid:13) (cid:16)(cid:23) 5(cid:16)6. -(cid:12)2(cid:22)(cid:18),* (cid:16). (cid:16)(cid:23) 5(cid:16)6. (cid:15)(cid:22).(cid:13)* ! (cid:11)2(cid:16)6(cid:18)(cid:14) (cid:11)(cid:22)50 $(cid:8) $(cid:11) =(cid:22)(cid:11) (cid:25)(cid:12)(cid:23)(cid:13)(cid:20)(cid:16)(cid:23)(cid:12)(cid:14) (cid:12)(cid:22).(cid:18)(cid:20)(cid:12).* ! 4(cid:23)(cid:16)= =(cid:12) 2(cid:22)(cid:14) (cid:22) -.(cid:20)(cid:12), (cid:14)(cid:20)(cid:11)(cid:24)6(cid:11)(cid:11)(cid:20)(cid:16)(cid:23) (cid:22)-(cid:16)6(cid:13) (cid:22)(cid:23)5 6(cid:15)(cid:14)(cid:22)(cid:13)(cid:12)(cid:11) =2(cid:12)(cid:23) (cid:4) (cid:4) (cid:2) (cid:2) (cid:26) (cid:26) (cid:5) (cid:5) (cid:7) (cid:7) (cid:28) (cid:28) (cid:9) (cid:9) (cid:10) (cid:10) (cid:27) (cid:27) (cid:4)(cid:6) (cid:4)(cid:6) (cid:4)(cid:4) (cid:4)(cid:4) (cid:4)(cid:2) (cid:4)(cid:2) (cid:4)(cid:26) (cid:4)(cid:5) (cid:4)(cid:7) (cid:4)(cid:28) (cid:4)(cid:28) (cid:4)(cid:9) (cid:4)(cid:9) (cid:4)(cid:10) (cid:4)(cid:10) (cid:4)(cid:27) (cid:4)(cid:27) (cid:2)(cid:6) (cid:2)(cid:6) (cid:2)(cid:4) (cid:2)(cid:2) (cid:2)(cid:26) (cid:2)(cid:5) (cid:2)(cid:7) (cid:26)(cid:26)(cid:9)(cid:8)(cid:2)(cid:28)(cid:28)(cid:8)(cid:2)(cid:4)(cid:6)(cid:2) (cid:7)(cid:6)(cid:5)(cid:8)(cid:9)(cid:2)(cid:2)(cid:8)(cid:4)(cid:10)(cid:6)(cid:4) (cid:29)(cid:30)(cid:31) (cid:29)!"!#$"!%& #’%()* (cid:29)(cid:29)+ (cid:11)(cid:12)(cid:13)(cid:14)(cid:12)(cid:15)(cid:16)(cid:17)(cid:18)(cid:12)(cid:19)(cid:18)(cid:20)(cid:13)(cid:20)(cid:21)(cid:22)(cid:13)(cid:20)(cid:16)(cid:23)(cid:8)(cid:24)(cid:16)(cid:25) (cid:2)(cid:7)(cid:7)(cid:8)(cid:2)(cid:27)(cid:4)(cid:28)(cid:7)(cid:27)(cid:7) (cid:9)(cid:4)(cid:26)(cid:8)(cid:10)(cid:6)(cid:7)(cid:8)(cid:27)(cid:2)(cid:5)(cid:27) (cid:14)(cid:15)(cid:11)(cid:16)(cid:17)(cid:18)(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:15)(cid:15)(cid:23)(cid:24)(cid:25)(cid:21)(cid:26)(cid:20)(cid:11)(cid:5)(cid:24)(cid:27)(cid:23)(cid:24)(cid:28)(cid:22)(cid:18)(cid:21)(cid:24)(cid:29)(cid:30)(cid:24)(cid:31)(cid:11) (cid:22)(cid:20)(cid:24)!(cid:8)(cid:4)(cid:2)(cid:7)(cid:2)"(cid:3)(cid:7)(cid:3)(cid:13)"(cid:7)(cid:12)(cid:9)(cid:13)(cid:13)# (cid:2)(cid:3)(cid:4)(cid:5)(cid:2)(cid:2)(cid:6)(cid:6)(cid:7)(cid:5)(cid:5)(cid:8)(cid:6)(cid:7)(cid:8)(cid:6)(cid:4)(cid:3)(cid:7)(cid:6)(cid:8)(cid:3)(cid:4)(cid:7)(cid:9)(cid:9)(cid:10)(cid:4)(cid:11)(cid:5)(cid:12)(cid:13)(cid:8)(cid:11)(cid:2)(cid:6)

=== Sample Exhibit Objections ===

Sample Exhibit List and Objections Joint Exhibits Exhibit no. Description J-1 Acme Corp. First Report of Injury Plaintiff’s Exhibits Exhibit no. P-1 P-2 Description Objection Response Medical Records - Ochsner Hearsay Medical Bills of Plaintiff Authenticity FRE 803(4) Plaintiff will authenticate Defendant’s Exhibits Description Objection Response Safety meeting minutes Hearsay FRE 803(6) Exhibit no. D-1 D-2

=== ERISA Case Management Order ===

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA SAMPLE CIVIL ACTION NO: PLAINTIFF VERSUS DEFENDANT SECTION: "H" (__) ERISA CASE MANAGEMENT ORDER This case appears to be an action seeking benefits under the provisions of an employee benefit plan pursuant to the Employee Retirement Income Security Act of 1974, 29 U.S.C. §§ 1001-1461 ("ERISA"). Accordingly, pursuant to Rule 16(b) of the Federal Rules of Civil Procedure, the Court establishes the following days following its entry into the record. scheduling order. Any objections to this Order must be filed no later than seven SAMPLE In order to facilitate an efficient resolution of this action, the following I. Within 60 days of the date of this Order, the parties shall file a (1) ORDERS are entered: joint stipulation, (2) statement, or (3) motion for summary judgment or other dispositive motion as to the following issues: a. whether ERISA governs the employee benefit plan at issue; b. whether the plan vests the administrator with discretionary authority to determine eligibility for benefits and/or construe and interpret the terms of the plan; and employee benefit plan at issue. c. whether ERISA preempts all state law claims related to the SAMPLE II. Within 60 days of the date of this Order, Defendant shall file: (A) a complete copy of the employee benefit plan and summary plan description, and (B) a copy of the complete administrative record concerning Plaintiff’s claim for benefits. Defendant shall also deliver one hard copy of these items to chambers III. Within 90 days of the date of this Order, Plaintiff shall file a in a three ring binder. All documents must be numbered or bates stamped. SAMPLE statement regarding the completeness of the administrative record. If Plaintiff contends that the administrative record is incomplete in any way, Plaintiff shall describe the alleged omitted documents and shall set forth the basis for the contention that the documents were improperly omitted. If Plaintiff possesses the documents, copies shall be proffered to the Court along with such statement, subject to Defendant’s right to object. IV. Absent further order, discovery in this case is limited as provided by Fifth Circuit precedent.1 If a diligent review of the law and facts leads a party filed promptly. to believe that there is a basis for expanding the scope of discovery in this case, an appropriate motion and memorandum, citing applicable authority, should be SAMPLE V. Counsel shall deliver a hard copy of any pleadings, along with any attachments and exhibits, that together exceed 50 pages in total length to chambers at 500 Poydras Street, Room C-206 for the Court's use. This copy must be placed in a three ring binder, tabbed, and reflect pagination and document numbers consistent with the electronic document stamping of CM/ECF. VI. Following the completion of items I-III of this Order, the parties must attend a settlement conference with the assigned magistrate judge. The parties must contact the assigned magistrate judge within 30 days of the entry of this must be held no later than 180 days following the entry of this Order. Order for the purpose of scheduling a settlement conference. The conference SAMPLE 1 See generally Vega v. National Life Ins. Co., 188 F.3d 287 (5th Cir. 1999); Crosby v. Louisiana Health Serv. & Indem. Co., 647 F.3d 258 (5th Cir. 2011). Discovery may not be conducted regarding the factual basis of the plaintiff's medical claim. Crosby, 647 F.3d at 263. VII. After completion of items I-III of this Order, the Court will issue a briefing order. SAMPLE JANE TRICHE MILAZZO UNITED STATES DISTRICT JUDGE Issued for the Court: By: s/Erin McNamara Case Manager 504-589-7695 SAMPLE SAMPLE

=== Sample Pre-Trial Order ===

Case -JTM-KWR Document 376 Filed 02/18/14 Page 1 of 28 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA BEHALF OF HER MINOR CHILD, M.H., INDIVIDUALLY AND ON Plaintiffs v. CASE NO: MCNEIL CONSUMER HEALTHCARE, a Division of MCNEIL-PPC, INC.; and JOHNSON & JOHNSON, Defendants. JUDGE JANE TRICHE MILAZZO MAGISTRATE KAREN WELLS ROBY PRETRIAL ORDER 1. The date of the Pretrial Conference is Thursday February 20, 2014 at 1:45 PM. 2. The following counsel appeared at the Pretrial Conference: a. Representing the Plaintiff: b. Representing the Defendants: Case JTM-KWR Document 376 Filed 02/18/14 Page 2 of 28 3. Parties; a. The Plaintiff is , individually and on behalf of her minor child, M.H. b. The Defendants are: i. McNeil Consumer Healthcare, a Division of McNEIL-PPC, Inc. (Plaintiff also named McNeil Consumer Healthcare, an unincorporated division of McNEIL- PPC, Inc.); and ii. Johnson & Johnson. 4. Jurisdiction: a. Jurisdiction is based on a complete diversity of citizenship of all parties. i. Plaintiff: The plaintiff is a resident of Texas. ii. Defendants: 1. McNEIL-PPC, Inc. is a New Jersey corporation, with its principal place of business in New Jersey (McNeil Consumer Healthcare is an unincorporated division of McNEIL-PPC, Inc.). 2. Johnson & Johnson is a New Jersey corporation, with its principal place of business in New Jersey. b. The parties stipulate that the amount in controversy, exclusive of interest and costs, exceeds $75,000. 5. Motions: a. The following motions are pending: 1. Defendants' Motion In Limine No. 2 Concerning the Alleged Inadequacy of FDA's Drug Safety Monitoring; . 2. Defendants' Motion In Limine No. 3 Concerning Other Lawsuits, Claims or Settlements Involving Children's Motrin or Other Ibuprofen Products; 2 Case -JTM-KWR Document 376 Filed 02/18/14 Page 3 of 28 3. Defendants' Motion In Limine No. 4 Concerning Non-Ibuprofen Products Withdrawn or Removed From The Market; 4. Defendants' Motion In Limine No. 5 Concerning McNeil's Voluntary Recalls; and 5. Defendants' Motion In Limine No. 6 Concerning the Number of Lawyers Representing Defendants and Whether A Corporate Representative is in the Courtroom. b. The following additional motions are contemplated concerning special issues appropriate for determination in advance of trial on the merits: i. Plaintiffs and Defendants intend to file motions in limine on various evidentiary issues. ii. Plaintiff has sued 2 separate defendants. Counsel for the 2 separate defendants intend to each make an opening statement, individually examine and cross-examine witnesses, and make closing arguments. Plaintiffs will object given Plaintiffs' assertion that the Defendants are so closely aligned with respect to Plaintiffs' claims in this case, that such an arrangement would result in duplicative argument and examination. iii. Pursuant to this Court's Order (Doc. No. 357), the Plaintiff and Defendants have submitted pretrial briefing on the issue of preemption. . 6. A brief summary of the material facts claimed by: a' Plaintiff: In the afternoon and evening of February 4, 2010 Plaintiff gave M.H. Children's Motrin for fever. By early the next morning M.H. had developed a rash which progressed rapidly over the course of the morning. Plaintiff immediately sought emergency medical help for M.H. who was admitted to Ochsner Medical Center with a severe "rash" and skin sloughing. At Ochsner M.H. was tested for virus which proved negative. M.H. was ultimately diagnosed with Toxic Epidermal Necrolysis (TEN) a serious, painful, life threatening, disfiguring disease that manifested itself over large areas of M.H.'s body. Because the treatment for TEN is similar to the treatment of severe bum victims, TEN patients, as a matter of the standard of care, are treated in burn units. Once diagnosed with TEN M.H. was transferred to and underwent treatment at the Baton Rouge General Bum Center. M.H. remained at the Burn Center until her ultimate release on March 18,2010. Due to her ingestion of Children's Motrin on February 4, 2010, Plaintiff incurred past medical costs in the amount of $ 233,000.00 Due to her ingestion of Children's Motrin on February 4, 2010, M.H. has sustained the following injuries: 3 Case -JTM-KWR Document 376 Filed 02/18/14 Page 4 of 28 1. Occular complications: M.H. suffers epiphora likely from a combination ectropion and scattered entropion with eyelashes irritating the cornea as found by Shriners Hospitals for Children. She has experienced ocular complication, including a fusion of her eyelids and will require ongoing medical care and treatment. In She has experienced a loss of most of the lower lid lashes. Such occular complications are quite common in TEN patients, severely affects the patient's quality of life and his or her functional abilities. will incur significant ocular medical expenses in the future. 2. Hyperpigmentation: The skin of M.H.'s entire body shows evidence of depigmentation and hyperpigmentation. Examination of he head reveals s torso shows very irregular, extensive blotchiness altered pigmentation, due to hyper and hypo pigmentation. Her extremities show the same altered pigmentation as well as a large hypertrophic scar of the right anterior thigh, secondary to a central intravenous line during her hospitalization. It is unclear that this time that any future medical care can improve this condition. The scarring on M.H. neck has recently required surgery to release the skin in her neck to allow her to turn her head and for which she is being evaluated for future surgery teeth are very irregular with a mix of primary and 3. Dental: M.H.'s secondary dentition. These findings are consistent with the authors conclusions as found in the article entitled Severe and Unrecognized Dental Abnormailities After Drug-Induced Epidermal Necrolysis. will likely incur significant dental medical expenses in the future. 4. Psychological Counseling: M.H. is currently being treated by for psychological issues often associated with TEN sequelae, and may be experiencing PTSA which is consistent with long term psychological sequelae afflicting many TEN patients. Due to the PTSD and the other psychological injuries one can expect to be associated with her gynecological injuries, it is reasonable to assume that will require long term psychological counseling in the future at significant expense. 5. Gynecological Injuries:M.H. has suffered labia minor fusion. Such gynecological complications consistent with the literature regarding vaginal damage resulting from SJS and TEN. Moreover, she is prescribed and uses Premarin cream daily due to the vaginal abnormalities. It is likely that she will require future medical care for her gynecological injuries. Moreover, there may be risk associated with the early and long term use of Premarin, necessitating additional medical treatment and cost. 4 Case -JTM-KWR Document 376 Filed 02/18/14 Page 5 of 28 Prior to giving the Children's Motrin to M.H., Plaintiff read the warnings on the label. Nothing in the label put her on notice that the Children's Motrin could cause a life threatening, life altering reaction such as TEN. Children's Motrin is a product manufactured by McNEIL-PPC, Inc. (McNeil). McNEIL-PPC, Inc. is a wholly owned subsidiary of Defendant Johnson & Johnson. McNeil Consumer Healthcare is a division of McNEILL-PPC, Inc. Johnson & Johnson retained and exercised control over material matters relating to adverse event reporting, safety signals and warnings associated with Children's Motrin. Causation: The single active ingredient in Children's Motrin is ibuprofen. Ibuprofen products, such as Children's Motrin, can and do cause SJS and TEN. There is a wealth of peer-reviewed epidemiological data involving case-control studies (SCAR- 1995, 2000, 2003, 2007; and Levi, et al. 2009 met analyses), case-series, and case report literature and spontaneous reports of good quality that support a finding that ibuprofen products such as Motrin and Children's Motrin cause SJS and TEN in both adults and children. In fact the prevalent view among researchers is that drugs are, in most cases, the cause of TEN. The only drug ingested by M.H. prior to the onset of TEN, that has been causally associated with TEN, was the Children's Motrin. Plaintiffs dispute the contention that M.H. experienced TEN symptoms prior to her ingestion of Children's Motrin. M.H.'s TEN was, in reasonable medical probability caused by the Children's Motrin. TEN is relatively rare, but the risk and severity of the disease out weights its benefits in the absence of adequate warning, particularly in light of the available alternatives. Defective Design: When McNeil delivered Children's Motrin into the market place it had a characteristic (ibuprofen) that rendered it unreasonably dangerous under Louisiana law in that there is a feasible safer alternative to the active ingredient ibuprofen and the risk of the very serious injuries associated with ibuprofen clearly outweigh the benefits of ibuprofen. The safer alternative is dexibuprofen which has been demonstrated to be as effective as ibuprofen but which has a much stronger safety profile. M.H.'s injuries were caused by ibuprofen and resulted from a reasonably anticipated use of the ibuprofen. At the time M.H. ingested Children's Motrin it was advertised for use by children as a pain reliever/fever reducer. The risk to M.H. would have been substantially less had dexibuprofen been the active ingredient in Children's Motrin instead of ibuprofen. Inadequate Warning: When McNeil delivered Children's Motrin into the market place it had a characteristic (ibuprofen) that rendered it unreasonably dangerous under Louisiana law in that the product label failed to adequately warn of the risk of life threatening injury such as TEN. McNeil and J&J are liable since when the Children's Motrin left McNeil's control, it had a characteristic that might cause damage and McNeil and J&J failed to use reasonable care to provide an adequate warning of that characteristic and its danger to users of the product. The injury which M.H. suffered was proximately caused by the ibuprofen, the characteristic of the product which made it unreasonably dangerous and existed at the time the product left the defendant's control. M.H. suffered actual and severe injury and the injury which M.H. suffered arose from a reasonably anticipated use of the children's Motrin. The 5 Case -JTM-KWR Document 376 Filed 02/18/14 Page 6 of 28 warning provided with the Children's Motrin in 2010 was inadequate to lead an ordinary user of Children's Motrin to think about the real danger in using the Children's Motrin, and then have the option of not using it. Label responsibility: Under the Federal Regulations, responsibility for the adequacy of drug labeling remains with the manufacturer and marketer of a drug, and not with the FDA. With respect to the drugs its manufacturers, including Children Motrin, McNeil has an obligation, under the Federal Regulations, to continuously review and assess all sources of adverse event information, to make comprehensive risk assessments, and to continuously review their labeling (at least annually) to assure that product safety information is correct and adequate. McNeil had this responsibility as long as they continued to manufacture and market the Children's Motrin. The obligation continued beyond the 2006 label change ordered by the FDA. The bottom line is the Federal Regulations impose an independent duty on McNeil and J&J to ensure that the labeling for Children's Motrin is accurate and adequate. The FDA has stated that the responsibility to ensure accurate information on warnings and risks solely rests with the drug company. The evidence is that McNeil failed to review the safety data and literature, and perform an assessment to ensure that their labeling post 2006 remained adequate. Safety Signals: There was a statistically significant increase in the incidence of SJS/TEN adverse event reporting for ibuprofen products between the date of the Children's Motrin label change in 2006 and the date M.H. ingested Children's Motrin in February 2010. The increase in adverse event reporting constituted a safety signal that the 2006 label was inadequate. The FDA relies on adverse event reporting and requires McNeil and J&J to monitor to McNeil as part of McNeil's ongoing responsibility to monitor its labels. McNeil and not the FDA retains responsibility for the label and for safety. McNeil has the authority and obligation to strengthen its label under the CFR when it should know that the label is inadequate. McNeil was aware of the increased rate of adverse event reporting for ibuprofen and SJS/TEN post he 2006 label change but did not conduct any investigation, study, or label comprehension analysis to determine if the 2006 Children's Motrin label was adequate. McNeil and J&J turned a blind eye to the increased incidence of SJS/TEN reporting and dismissed it as a media phenomenon. Acetaminophen: Contrary to Defendants' assertions, the 2013 FDA approved label for acetaminophen does not constitute a second rejection by the FDA of Plaintiffs' warnings claims, acetaminophen is a different compound with a better safety profile than ibuprofen. Louisiana Law: At the time of M.H.'s ingestion of Children's Motion, Plaintiffs were residents of New Orleans, Louisiana and the Children's Motrin was purchased in New Orleans, Louisiana. This is a diversity case and it is undisputed that Louisiana applies to the substantive issues in this case. Under Louisiana law Defendants are liable to Plaintiffs for defective design and inadequate warnings. The evidence will show that is was possible for Defendants to comply with both Federal and Louisiana 6 Case -JTM-KWR Document 376 Filed 02/18/14 Page 7 of 28 state law. Accordingly, Plaintiffs' claims are not preempted under any theory of preemption. Plaintiffs have provided this Court with briefing on the preemption issue. b. Defendants: McNEIL-PPC, Inc. manufactures Children's Motrin. Johnson & Johnson is a holding company that owns all of the stock of McNEIL-PPC, Inc. Johnson & Johnson does not manufacture or sell Children's Motrin. SJS/TEN: SJS and TEN are extremely rare and poorly understood diseases. The overall incidence rate is 1-2 cases per million persons per year from all causes. No test exists to identify the cause of an individual patient's SJS or TEN. Certain classes of medications are commonly associated with SJS and TEN, and many drugs can potentially cause these diseases, but there are also other causes - including infections. In many cases, a specific cause cannot be determined. The best available scientific evidence indicates that ibuprofen is unlikely to cause SJS or TEN. There are a number of highly suspect drugs that cause the majority of SJS and TEN cases, and ibuprofen is definitely not one of those highly suspect drugs. Confounding by Indication: The early (prodromal) symptoms of SJS and TEN are fever, headache and/or malaise. These are the very same symptoms for which consumers take OTC ibuprofen. As a result there are reported cases of SJS and TEN temporally associated with ibuprofen use where ibuprofen was probably taken after the disease had begun. The FDA Approved the Design and Warning: Children's Motrin is not unreasonably dangerous. The FDA approved both the chemical design of ibuprofen, and the warning label for Children's Motrin, determining that this product is so safe that it can be sold over-the-counter. Ibuprofen is one of the most widely used medications in the world. Design Claim Preempted by Federal Law: Mutual Pharmaceutical Co. v. Bartlett, 133 S. Ct. 2466 (2013), bars Plaintiffs state law design defect claim as a matter of law. Bartlett vacated a product liability judgment predicated on a jury's determination that an FDA-approved drug's active ingredient was unreasonably dangerous in design under state law because it could cause SJS/TEN. The judgment was vacated because it presented an irreconcilable conflict between state and federal law. Deeming a drug's active ingredient "unreasonably dangerous" imposes a duty on a manufacturer to redesign its drug and alter its active ingredient - but any change in the active ingredient renders the reformulated product a "new drug" under federal law which cannot be sold under federal law without prior FDA approval of both the new drug and its label. Thus, a state law requirement to change the formulation of an FDA approved drug conflicts with federal law and is preempted. Design Claim Fails Under State Law: Under Louisiana state law, Plaintiff must prove there is a feasible alternative design of ibuprofen. LSA-R.S. §9:2800.56. She claims that dexibuprofen is a safer alternative to ibuprofen. However, it is not legal to sell dexibuprofen in the U.S., and, thus, it was not (and is not) an available alternative 7 Case -JTM-KWR Document 376 Filed 02/18/14 Page 8 of 28 design. Second, dexibuprofen is a different drug from ibuprofen, and does not meet the alternative design requirement under the LPLA. Plaintiffs design defect claims premised specifically on dexibuprofen as a purported safer alternative design are preempted. Plaintiffs proposal requires McNeil to redesign ibuprofen and render it a "new drug" that cannot be sold under federal law without prior FDA approval. Under Bartlett, such a state law requirement to change the forumulation of an FDA approved drug conflicts with federal law and is, therefore, preempted. Warning Claim Preempted by Federal Law: In 2005, the FDA reviewed the risks and benefits of the class of medications known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen, to determine what warning language should be used on those drugs. Based on this review, the FDA told McNeil and all other manufacturers of these drugs that they should add a warning to the drug label advising consumers to stop use and see a doctor if skin reddening, rash or blisters appear. In addition, in 2006, the FDA specifically rejected a request that the label for OTC ibuprofen products be required to include a reference to "Stevens-Johnson syndrome" and/or "toxic epidermal necrolysis." The FDA also denied a request that the label include a warning that using the drug could lead to "serious and potentially life- threatening diseases" and/or "rare and' life-threatening reactions." McNeil has consistently used the language the FDA told it to use on the Children's Motrin label. Plaintiffs proposed alternative language runs counter to the FDA's directive that the OTC warning should include only easily-identifiable early symptoms of potential side effects, along with an instruction to stop use and see a doctor if they appear. Plaintiff contends that the Children's Motrin label should have included not just the FDA-specified listing of potential initial symptoms of SJS/TEN ("skin reddening," "rash," and "blisters"), but also warnings about potential severe and permanent injuries such as major skin loss, blindness, scarring, disability, and disfigurement. But the FDA has now twice made clear—in 2005 for NSAIDs (which include ibuprofen products such as Motrin and naproxen products such as Aleve) and in August 2013 for drugs containing acetaminophen (which include Tylenol)—that the only SJS/TEN warnings the agency considers appropriate for the OTC labeling of these widely-used consumer pain and fever medications are warnings about the initial symptoms, coupled with instructions to stop use and seek medical attention right away. Plaintiffs claim that the OTC Children's Motrin label should have specifically warned about "TEN" or of a "life threatening" reaction is preempted. In 2006, the FDA expressly rejected a request that the label for OTC ibuprofen products be required to include a reference to "TEN." The FDA also rejected a request that the label include a warning that using the drug could lead to "serious and potentially life- threatening diseases" and "rare and life-threatening reactions." This is "clear evidence" that the FDA would not approve Plaintiffs proposed warnings. See Wyeth v. Levine, 555 U.S. 555, 571 (2009) (holding that federal law preempts state-law 8 Case -JTM-KWR Document 376 Filed 02/18/14 Page 9 of 28 failure-to-wam claims where there is "clear evidence that the FDA would not have approved" unilateral labeling change by manufacturer). Likewise, any claim that the OTC Children Motrin's label should have included the same warnings as the prescription Motrin label - including an explicit reference to "SJS/TEN" - is preempted. The FDA considered and specifically rejected a wattling on OTC ibuprofen products that would have mentioned SJS/TEN. See id Moreover, under FDA regulations, the standard for an OTC label is materially different from the standard for a prescription label. Over-the-counter drug labels are written to provide consumers with information that will help them use the drug safely. See 21 C.F.R. § 330.10 (4)(v) (stating that an OTC label should be "in such terms as to render them likely to be read and understood by the ordinary individual, including individuals of low comprehension, under customary conditions of purchase and use"). Prescription drug labels, by contrast, are written for doctors. They provide information about the drug's risks and benefits that prescribing physicians consider, along with a patient's medical history, when deciding whether the drug is appropriate for a particular individual. See 21 C.F.R. § 201.57 (a)(10) (a prescription label should contain "information that would affect decisions about whether to prescribe a drug, recommendations for patient monitoring that are critical to safe use of the drug, and measures that can be taken to prevent or mitigate harm."). Most recently, the FDA reaffirmed the distinction between prescription and OTC labeling when it decided to require a warning on the early symptoms of SJS/TEN for OTC acetaminophen products — rather than a detailed listing of severe complications the FDA required for prescription acetaminophen products — based on its view that OTC warnings about SJS/TEN should simply allow consumers to "recognize and react quickly to the initial symptoms" of those diseases. (Consumer Updates, "FDA Warns of Rare Acetaminophen Risk." Aug. 1,2013.) In its August 2013 announcement of the new warnings required for OTC acetaminophen products—which also expressly references the agency's earlier- mandated warnings for NSAIDs including OTC ibuprofen and naproxen—the FDA explained its rationale. The FDA was well aware of the severe potential consequences of SJS/TEN, and indeed cited the severity of the disease as the reason for requiring the warnings. But the FDA also recognized, as it had recognized for NSAIDs when it previously rejected a stronger SJS/TEN warning for NSAIDs, that acetaminophen was a widely-used and beneficial consumer medication, and the incidence of SJS/TEN associated with its use was both rare and unpredictable. The OTC labeling changes therefore were "not intended to wony consumers or health care professionals, nor ... to encourage them to. choose other medications," but to allow consumers to "recognize and react quickly to the initial symptoms of these rare[,] but serious, side effects, which can be fatal." As this explanation makes plain, the FDA's decision to warn only about the potential initial symptoms of SJS/TEN on OTC labeling reflects a considered regulatory judgment balancing the competing objectives of providing adequate information for safe use while avoiding alarmist descriptions of rare and unpredictable potential side effects that might deter 9 Case -JTM-KWR Document 376 Filed 02/18/14 Page 10 of 28 beneficial use. This is clear evidence that the FDA would have rejected the warnings about severe and permanent injuries that Plaintiff alleges should have been on the OTC Children's Motrin label. Warning Claim Fails Under State Law: The label used for OTC Children's Motrin is the same label used by all OTC ibuprofen manufacturers. The language at issue in that label was written and approved by the FDA. McNeil did not act unreasonably when it used the warnings that the FDA told it, and every other ibuprofen manufacturer, to use. M.H.'s TEN was Not Caused by Children's Motrin: M.H. had the prodromal symptoms of TEN before she was allegedly given Children's Motrin. Furthermore, the time to onset between when she was reportedly given that drug and when she experienced mucocutaneous signs and symptoms was only an hour - not the typical 3-4 days that would be expected. Individual Claims are Prescribed: filed this lawsuit on February 24, 2011, more than one year after February 5, 2010 - the date her daughter had clearly developed SJS and/or TEN and also the date that Plaintiff learned what may have caused that disease. After M.H. awoke with rash/hives-like bumps all over her face and neck at 3-4 AM on February 5, 2010, Plaintiff called her sister, and her sister told her that M.H.'s condition might be a reaction to medication. Therefore, Plaintiff did not give her daughter any more medication. On that same day, the ER physician at Ochsner Medical Center told Plaintiff that M.H.'s TEN may have been caused by medication. Further, prior to M.H.'s discharge from Ochsner on February 8, 2010, a second physician told Plaintiff that her daughter's TEN may have been caused by medication. Plaintiffs Claims Preempted Under Buckmcm: To the extent Plaintiff bases any of her claims on McNeil's alleged failure to provide relevant or complete safety information about ibuprofen to the FDA, such claims are preempted under Buckmcm Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 348 (2001) (holding that state-law claims that allege that the defendant withheld from or otherwise misrepresented information to the FDA are preempted). Therefore, under Buckman, Plaintiffs claims are preempted to the extent they are based on any allegation that McNeil failed to report information it was required to report to the FDA, including any adverse event reports. 7. A single listing of all uncontested material facts: ' a. McNEIL-PPC, Inc. is the "manufacturer" of Children's Motrin, as the term "manufacturer" is used in the Louisiana Products Liability Act. b. M.H. awoke with bumps on her face and neck in the early morning hours of February 5,2010. 10 Case -JTM-KWR Document 376 Filed 02/18/14 Page 11 of 28 c. called her sister early in the morning on February 5,2010, and her sister told her that M.H.'s condition might be a reaction to the medication d. After speaking with her sister early in the morning on February 5, 2010, did not give M.H. any more medication on February 5,2010. A single listing of the contested issues of fact: a. Whether M.H. was given Children's Motrin on February 4,2010? b. If M.H. was given Children's Motrin on February 4,2010, did that occur before or after her prodromal symptoms of TEN were already present? c. If M.H. was given Children's Motrin on February 4, 2010, did that occur before or after her rash appeared? d. Whether M.H.'s SJS/TEN was caused by Children's Motrin? e. Whether Children's Motrin is unreasonably dangerous in design? f. Whether Children's Motrin is unreasonably dangerous due to an inadequate warning? g. The nature and extent of the injuries sustained by M.H. and any alleged disability? h. The nature and extent of general damages sustained by M.H.? i. The nature and extent of M.H.'s special damages pre-majority? j. The nature and extent of M.H.'s special damages post-majority? k. The nature and extent of general damages sustained by as a result of her daughter's TEN? 1. Whether ' individual claims are barred by prescription because this lawsuit was not filed timely? m. The extent to which TEN is attributable primarily to drug ingestion. n. Whether ibuprofen can cause TEN. o. Whether Children's Motrin can cause TEN. p. Whether dexibuprofen is a safer alternative to ibuprofen. q. Whether dexibuprofen is a feasible alternative to ibuprofen. 11 Case -JTM-KWR Document 376 Filed 02/18/14 Page 12 of 28 r. Whether it is technically, scientifically and economically feasible to manufacture ibuprofen in a single molecule version isolating the active molecule of ibuprofen known as dexibuprofen from the inactive molecule known as levoibuprofen and whether the result is a purer form of ibuprofen. s. Whether McNeil and J&J had authority to strengthen the warnings in its 2006 label prior to the time M.H. ingested Children's Motrin. t. Whether McNeil and J&J had the responsibility to strengthen the warnings in its 2006 label prior to the time M.H. ingested Children's Motrin. u. Whether Defendants' ignored safety signals impacting the adequacy of the Children's Motrin label in 2010. v. Whether there was an increase in the rate of SJF/TEN adverse event reports related to ibuprofen ingestion between the label change for Children's Motrin in 2006 and the ingestion of Children's Motrin by M.H. in February 2010. w. Whether Acetaminophen has a better safety profile than ibuprofen. x. Whether read the warnings on the Children's Motrin label prior to giving the Children's Motrin to M.H. y. Whether McNeil and J&J have never sought FDA approval for dexibuprofen. z. Whether as early as 1993 Defendants filed a patent related to an application of dexibuprofen to its Pepcid and Mylicon products. In this patent, Defendants stated that compared to regular/racemic ibuprofen that dexibuprofen is more effective: 1) dexibuprofen works faster for head and stomach ache relief; (2) dexibuprofen provides enhanced relief of aches and pains; (3) dexibuprofen offers faster onset of pain-relief and inflammation relief. Defendants' patents further state that compared to regular racemic ibuprofen, dexibuprofen is safer in that (1) it has a lower risk of allergic reaction; (2) it produces a lower metabolic load on the body; it produces less deposits in the body's fatty tissues; (3) and that dexibuprofen has a lower incidence rate of adverse reactions that were significantly lower. aa. Whether, in spite of any action on the part of the FDA, McNeil and J&J retain responsibility for the safety of its products and the adequacy of its labels. 9. A single listing of the contested issues of law: a. Whether the recent U.S. Supreme Court decision of Mutual Pharmaceutical Co. v. Bartlett, 133 S. Ct. 2466 (2013), bars Plaintiffs state law claim that there is an inherent risk of SJS or TEN associated with ibuprofen and that Louisiana law 12 Case -JTM-KWR Document 376 Filed 02/18/14 Page 13 of 28 therefore imposes a duty on the Defendants to redesign Children's Motrin by changing the formulation of the active ingredient from ibuprofen to dexibuprofen? b. Whether, as a matter of law, Louisiana state law permits recovery for damages allegedly caused by an unreasonably dangerous design when the product at issue is an OTC drug that is one of the most widely used medications in the world that has been approved as both safe and effective by the FDA for decades, when the Plaintiffs proposed alternative design, dexibuprofen, is: i. A different drug from ibuprofen; and ii. Was not (and is not) legally available for sale in the United States? . c. Whether Plaintiffs state law claim that the warning on OTC Children's Motrin is inadequate is preempted because, under the U.S. Supreme Court's decision in Wyeth v. Levine, 555 U.S. 555 (2009), there is "clear evidence" that the FDA would not have approved the changes to the Children's Motrin warning label proposed by Plaintiff? d. Whether, as a matter of law, Louisiana state law permits recovery for damages allegedly caused by an inadequate warning if the product at issue is an OTC medication regulated by the FDA and the language at issue in the warning was written and approved by the FDA? e. Whether, as a matter of law, individual claims, including those for medical expenses incurred by M.H. during her minority, are barred by prescription because this lawsuit was not filed until February 24,2011? f. Whether, as a matter of law, Plaintiffs claims based on McNeil's alleged failure to provide relevant or complete safety information about ibuprofen to the FDA are preempted under Bnchnan Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 348 (2001)? 10. A list and description of the exhibits that each party intends to introduce at trial are attached as Appendices 1 and 2 to this Pretrial Order. The list first describes those exhibits that are to be admitted without objection. It then describes those to which there will be an objection, noting by who the objection is made and the nature of the objection. 11. A list of all deposition testimony that each party intends to offer into evidence at trial is attached as Appendices 3 and 4 to this Pretrial Order. 12. A list and brief description of any charts, graphs, models, schematic diagrams, and similar objects which, although not to be offered in evidence, respective counsel intend to use in opening or closing arguments: 13 Case -JTM-KWR Document 376 Filed 02/18/14 Page 14 of 28 a. Plaintiff: In addition to blowups of those documents and things identified on the Exhibit List, Plaintiff may use an easel and writing pad, computer projection, monitors/screens. b. Defendants: In addition to those documents and things identified on the Exhibit List, Defendants may use an easel and writing pad. 13. Witnesses: a. A list of witnesses for all parties, including the names, addresses, and statement of the general subject matter of their testimony (it is not sufficient to designate the witness simply "fact," "medical," or "expert"), and an indication in good faith of those who will be called in the absence of reasonable notice to opposing counsel to the contrary: i. Plaintiff: I. Witnesses Plaintiffs Will Call WITNESS ADDRESS SUBJECT MATTER L/D Ph.D. Department Of Clinical And Administrative Sciences College Of Pharmacy, University Of Georgia Athens, Georgia 30602-2354 , Ph.D. Columbia University Department of Statistics 14 Live Live Dr. will testify regarding the matters set forth in his expert report and disclosures, including his qualifications and general causation of S JS/TEN by ibuprofen products, including Children's Motrin; causation of M.H.'s TEN; sequelae of TEN; FDA regulations regarding labeling and post label pharmacovigilance; scope of safety investigations by the FDA; the temporal relationship between the administration of ibuprofen, including Children's Motrin and the onset of SJS/TEN; knowledge and investigation of Defendants and FDA regarding the risk of SJS/TEN; adequacy of Children's Motrin label. will testify regarding Dr. the matters set forth in his expert report, disclosures and deposition regarding his findings concerning AERs/MedWatches and other reports reflected in the drug safety Case -JTM-KWR Document 376 Filed 02/18/14 Page 16 of 28 WITNESS ADDRESS SUBJECT MATTER L/D R. Ph.D. University of California San Francisco School of Pharmacy M.D. , Loyola University of Chicago, Strich School of Medicine M.H. c/ and the sequelae of M.H.'s TEN, will testify regarding the Dr. matters set forth in his report, deposition and disclosures including his qualification, his label comprehension studies methodology and results, label comprehension studies in general. will testify regarding Dr. his qualifications to treat SJSATEN patients; the treatment in bum units of SJS/TEN patients; the care and treatment of M.H. Mother of M.H. will testify about the events surrounding M.H.'s ingestion of Children's Motrin, her resulting TEN and the course of treatment for the TEN, M.H.'s injuries and concerns. will testify Sister of regarding the report of M.H.s ingestion of Children's Motrin on February 4,2010 's will Family friend of the testify regarding her observations as to M.H.s injuries and limitations. Live Live Live Live Live Her experience with TEN and her ongoing issues with the sequelae of TEN. Live 11. Witnesses Plaintiffs May Call WITNESS ADDRESS SUBJECT MATTER L/D Mother of regarding her observation of the medications consumed by M.H. on will testify Live 16 Case -JTM-KWR Document 376 Filed 02/18/14 Page 21 of 28 WITNESS ADDRESS SUBJECT MATTER L/D Children's Choice Pediatrics The care and treatment of M.H. Live MD Dr. M.D., Ph.D. MD Children's Medical Center The care and treatment of M.H. Live The care and treatment of M.H. Live Live Dr. may be called as a rebuttal witness to rebut the testimony and/or computations and/or report of Dr. , including but not limited to his calculations regarding "multivariate relative risk" (regardless of who testifies regarding those computations) and the testimony and/or report of Dr. regarding causation, including the ALDEN score relied on by Dr. relationship to EuroSCAR. and its Plaintiffs also identify any individuals, including but not limited to records custodians, who may be needed to authenticate documents for all treating physician offices and hospitals involved in the care and treatment of M.H.. Plaintiff may call any witness identified by Defendants. ii. Defendants: I. Witnesses Defendants Will Call WITNESS ADDRESS SUBJECT MATTER MD Will testify as an expert regarding (a) principles of pediatric infectious 21 Live, by Deposition or by Affidavit Live or Deposition L/D Live Case -JTM-KWR Document 376 Filed 02/18/14 Page 23 of 28 II. Witnesses Defendants Mav Cai! WITNESS ADDRESS SUBJECT MATTER c/o McNeil c/o McNeil Former McNeil employee, testimony regarding adverse event reporting and medical communications. Current McNeil employee, testimony regarding medical communications and marketing issues. L/D Live Live MD , MD PhD , , MD MD MD . c/o McNeil c/o McNeil The care and treatment of M.H. Live The care and treatment of M.H. Live Live or deposi tion Live The care and treatment of M.H.. May testify as an expert, from a statistical perspective, on the results concerning the association between SJS/TEN and exposure to ibuprofen (among other drugs) reported in two peer-reviewed epidemiological studies - SCAR and EuroSCAR. See expert report. He may also rebut evidence presented by Plaintiffs experts. The care and treatment of M.H.. Live The care and treatment of M.H.. Live The care and treatment of M.H.. Testimony regarding pharmacovigilance processes and analysis. Testimony regarding pharmacovigilance processes and analysis. Live Live Live 23 Case TM-KWR Document 376 Filed 02/18/14 Page 25 of 28 WITNESS ADDRESS SUBJECT MATTER L/D Plaintiffs experts. The care and treatment of M.H.. Live or deposi tion MD MD The care and treatment of M.H.. Live The care and treatment of M.H.. Live Defendants also identify any individuals, including but not limited to records custodians, who may be needed to authenticate documents for all treating physician offices and hospitals involved in the care and treatment of M.H.. Live Defendants may call any witness identified by Plaintiff. Live or Deposi tion b. Witnesses were identified in accordance with Rule 26 Pretrial Disclosures and written discovery propounded by the parties, in accordance with the Federal Rules of Civil Procedure and prior court orders. No other witnesses shall be allowed unless agreeable to all parties and their addition does not affect the trial date. This restriction will not apply to rebuttal witnesses or documents whose necessity cannot be reasonably anticipated. In the case of expert witnesses, counsel certifies that they have exchanged expert reports in accordance with the Federal Rules of Civil Procedure and prior court orders. Expert witnesses whose reports have not been furnished to opposing counseled shall not be permitted to testify nor shall experts be permitted to testify to opinions not included in the reports timely furnished. c. Except for good cause shown, the Court will not permit any witness to testify with respect to such witness there has been complete compliance with all provisions of the pre-trial order and prior court orders. d. Counsel shall not be allowed to ask questions on cross-examination of an economic expert which would require the witness to make mathematical calculations in order to frame a response unless the factual elements of such questions shall have been submitted to that expert witness not less than three full working days before trial. 25 Case -JTM-KWR Document 376 Filed 02/18/14 Page 26 of 28 14. This is a jury case. a. The jury trial is applicable to all aspects of this case. Proposed jury instructions, special jury interrogatories, and trial memoranda shall be electronically filed with the Court not later than ten working days prior to the trial date; and any special questions that the Court is asked to put to prospective jurors on voir dire shall be electronically filed with the Court not later than five working days prior to the trial date unless specific leave to the contrary is granted by the Court. b. A trial memorandum shall be required only when and to the extent ordered by the Court. However, any party may in any event file such memoranda not less than five working days prior to trial and should accomplish this with respect to any anticipated evidentiary problems which require briefing and jury instructions requiring explanation beyond mere citation to authority. 15. Defendants propose that the issue of liability should be tried separately from that of quantum. Plaintiffs object and assert that the issues should be tried together. 16. Other matters that might expedite a disposition of the case: 17. Trial shall commence on March 17, 2014 at 8:30 AM. The Defendants estimate that trial will take 15 trial days. Plaintiffs essentially concur that the trial will take 10-15 trial days. 18. This pretrial order has been formulated after conference at which counsel for the respective parties have appeared in person. Reasonable opportunity has been afforded counsel for corrections, or additions, prior to signing. Hereafter, this order will control the course of the trial and may not be amended except by consent of the parties and the Court, or by order of the Court to prevent manifest injustice. 19. Possibility of settlement of this case was considered. THIS THE IS"1 day of February, 2014. Attorneys for Plaintiffs 26 Case -JTM-KWR Document 376 Filed 02/18/14 Page 27 of 28 ON BEHALF OF HER MINOR CHILD, M.H. INDIVIDUALLY AND Attorneys for Defendants MCNEIL CONSUMER HEALTHCARE DIVISION OF MCNEIL-PPC, INC.; and JOHNSON & JOHNSON UNITED STATES DISTRICT JUDGE 27